BetaInsiders sold $51.2M in the past 12 months.100% was sold under disclosed trading plans. The largest seller, David Wang (Officer, Director), sold $29.0M. 98% of these sales were shares from exercising options.Share-of-stake figures for this company are being verified and will be added when that check is finished. Why
Routine activity: 100% of sales were under disclosed plans, and no insider sold more than 1% of vested holdings.
A share of stake is shown for 0 of the 8 officers and directors who sold. 9 are left out Disclosed company stock is not an insider's whole wealth.i
Left out: David Wang, Haiping Dun, Jian Wang, Tracy Liu, Sotheara Cheav, Lisa Feng, Mark McKechnie, Fuping Chen and Charles Pappis (share of stake is being verified).
Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.
Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
No officer or director trades were reported for the past 30 days. The most recent before that:
| Who | Shares | Price | % of total stake | Total stake after | Trade date | Filed |
|---|---|---|---|---|---|---|
| David Wang Officer, Director | 70,000 | $74.59 | n/a | n/a | Sep 9, 2026 | Sep 10, 2026 |
No. Jian Wang reported no open-market sales in the past 12 months.
Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 100% of sales by value ran under 10b5-1 trading plans disclosed in the filings. A trading plan schedules sales in advance.
No. Officers and directors reported no purchases in the past 12 months.
| Who sold | Amount | % of holdings | Trading plan |
|---|---|---|---|
| David Wang Officer, Director | $29.0M 480K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Mark McKechnie Chief Financial Officer and Treasurer | $9.8M 185K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Fuping Chen Vice President, Sales-China of ACM Research (Shanghai), Inc., a subsidiary of the Issuer | $4.0M 120K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Tracy Liu Director | $2.9M 60K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Lisa Feng Chief Financial Officer of ACM Research (Shanghai), Inc., a subsidiary of the Issuer | $2.4M 60K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Sotheara Cheav Senior Vice President, Manufacturing of ACM Research (Shanghai), Inc., a subsidiary of the Issuer | $1.6M 19K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Haiping Dun Director | $954K 15K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Charles Pappis Director | $510K 10K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.
| Insider | Held Oct 13, 2025 | Sold | Held Oct 13, 2026 | Still held | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
David Wang!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for David Wang are complete. Officer, Director | n/a | −480K | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for David WangHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Wang are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($77.59 − strike price), using the most recent insider trade price on Form 4 (Sep 9, 2026), not a market close. | ||||||||||||||||||||||||
Haiping Dun!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Haiping Dun are complete. Director | n/a | −15K | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Haiping DunHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Haiping Dun are complete; balances and unit counts will be added when the check is finished. −755Kgifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($77.59 − strike price), using the most recent insider trade price on Form 4 (Sep 9, 2026), not a market close. | ||||||||||||||||||||||||
Jian Wang!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Jian Wang are complete. Chief Executive Officer and President of ACM Research (Shanghai), Inc., a subsidiary of the Issuer | n/a | 0 | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Jian WangHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jian Wang are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||||||||||||||
Tracy Liu!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Tracy Liu are complete. Director | n/a | −60K | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Tracy LiuHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Tracy Liu are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($77.59 − strike price), using the most recent insider trade price on Form 4 (Sep 9, 2026), not a market close. | ||||||||||||||||||||||||
Sotheara Cheav!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Sotheara Cheav are complete. Senior Vice President, Manufacturing of ACM Research (Shanghai), Inc., a subsidiary of the Issuer | n/a | −19K | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Sotheara CheavHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sotheara Cheav are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($77.59 − strike price), using the most recent insider trade price on Form 4 (Sep 9, 2026), not a market close. | ||||||||||||||||||||||||
Lisa Feng!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Lisa Feng are complete. Chief Financial Officer of ACM Research (Shanghai), Inc., a subsidiary of the Issuer | n/a | −60K | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Lisa FengHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Lisa Feng are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||||||||||||||
Mark McKechnie!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Mark McKechnie are complete. Chief Financial Officer and Treasurer | n/a | −185K | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Mark McKechnieHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mark McKechnie are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($77.59 − strike price), using the most recent insider trade price on Form 4 (Sep 9, 2026), not a market close. | ||||||||||||||||||||||||
Fuping Chen!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Fuping Chen are complete. Vice President, Sales-China of ACM Research (Shanghai), Inc., a subsidiary of the Issuer | n/a | −120K | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Fuping ChenHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Fuping Chen are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($77.59 − strike price), using the most recent insider trade price on Form 4 (Sep 9, 2026), not a market close. | ||||||||||||||||||||||||
Charles Pappis!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Charles Pappis are complete. Director | n/a | −10K | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Charles PappisHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Charles Pappis are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($77.59 − strike price), using the most recent insider trade price on Form 4 (Sep 9, 2026), not a market close. | ||||||||||||||||||||||||
Holdings and share of stake for ACM Research, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.
Officer and director open-market sales: $51.2M across 948,752 shares. Plan status and stated purpose are separate questions, and a sale can have both.
| Seller | Shares sold | Proceeds | Under a disclosed plan | Share of total | Sales dates |
|---|---|---|---|---|---|
| David Wang Officer, Director | 480K | $29.0M | 100% | 57% | Dec 3, 2025 to Sep 9, 2026 |
| Mark McKechnie Chief Financial Officer and Treasurer | 185K | $9.8M | 100% | 19% | Dec 4, 2025 to Aug 20, 2026 |
| Fuping Chen Vice President, Sales-China of ACM Research (Shanghai), Inc., a subsidiary of the Issuer | 120K | $4.0M | 100% | 8% | Dec 2, 2025 to Dec 3, 2025 |
| Tracy Liu Director | 60K | $2.9M | 100% | 6% | Mar 10, 2026 to Mar 11, 2026 |
| Lisa Feng Chief Financial Officer of ACM Research (Shanghai), Inc., a subsidiary of the Issuer | 60K | $2.4M | 100% | 5% | Nov 12, 2025 to Mar 6, 2026 |
| Sotheara Cheav Senior Vice President, Manufacturing of ACM Research (Shanghai), Inc., a subsidiary of the Issuer | 19K | $1.6M | 100% | 3% | Jun 4, 2026 to Jun 5, 2026 |
| Haiping Dun Director | 15K | $954K | 100% | 2% | Mar 9, 2026 to Aug 18, 2026 |
| Charles Pappis Director | 10K | $510K | 100% | 1.0% | Mar 5, 2026 to Apr 17, 2026 |
| Month | Sale proceeds | Disclosed plan | To cover taxes | No plan disclosed |
|---|---|---|---|---|
| Oct 2025 | $0 | $0 | $0 | $0 |
| Nov 2025 | $998K | $998K | $0 | $0 |
| Dec 2025 | $9.4M | $9.4M | $0 | $0 |
| Jan 2026 | $0 | $0 | $0 | $0 |
| Feb 2026 | $0 | $0 | $0 | $0 |
| Mar 2026 | $14.4M | $14.4M | $0 | $0 |
| Apr 2026 | $260K | $260K | $0 | $0 |
| May 2026 | $331K | $331K | $0 | $0 |
| Jun 2026 | $10.4M | $10.4M | $0 | $0 |
| Jul 2026 | $0 | $0 | $0 | $0 |
| Aug 2026 | $4.7M | $4.7M | $0 | $0 |
| Sep 2026 | $10.6M | $10.6M | $0 | $0 |
| Oct 2026 | $0 | $0 | $0 | $0 |
In line with the past 5 years. 8 insiders sold; the average is 7 a year.
| 12 months ending | Shares sold | Insiders who sold | Proceeds |
|---|---|---|---|
| Oct 13, 2026 Latest 12 months | 949K | 8 | $51.2M |
| Oct 13, 2025 1 year earlier | 1.02M | 8 | $26.3M |
| Oct 13, 2024 2 years earlier | 1.72M | 8 | $38.3M |
| Oct 14, 2023 3 years earlier | 548K | 6 | $8.0M |
| Oct 14, 2022 4 years earlier | 242K | 3 | $3.5M |
| Oct 14, 2021 5 years earlier | 2.63M | 8 | $75.4M |
Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.
Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for ACM Research, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.
External context: we only cite outside events when a documented connection exists. None is shown for this period.
All 253 Forms 3, 4 and 5 on record for ACM Research, Inc. (SEC CIK 1680062), filed from Nov 2, 2017 to Sep 10, 2026; 24 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.
Probable 3-for-1 stock split on or before Aug 16, 2022 (first filing that shows post-split balances). Splits aren't reported as transactions; 11 holding lines changed by exactly this ratio, so earlier share counts are restated.
Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.
Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".
| Name | Last filed | Last reported balance |
|---|---|---|
| Chenming Hu | Mar 19, 2025 | 100,002 shares, last reported balance as of Mar 17, 2025 |
| Xiao Xing | Oct 8, 2024 | 12,654,040 shares, last reported balance as of Oct 8, 2024 |
| Shanghai Science & Technology Venture Capital (Group) Co., Ltd. | Oct 8, 2024 | 12,494,476 shares, last reported balance as of Oct 8, 2024 |
| Yinan Xiang | Aug 24, 2021 | 3,438,510 shares, last reported balance as of Aug 24, 2021 |
| Fufa Chen | May 17, 2018 | 388,749 shares, last reported balance as of Jan 31, 2018 |
| Zhengfan Yang | Jan 26, 2018 | 2,500,002 shares, last reported balance as of Jan 8, 2018 |
| Min Xu | Nov 2, 2017 | No balance on record |
Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.